SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy (MSTR) is experiencing a surge in conversation following MSCI's recent decision not to exclude digital asset treasury companies from its global indexes. This move has ignited strong bullish sentiment, with many investors anticipating a potential short squeeze and significant upward movement now that a key bear thesis has been removed. The community is actively debating if this development, coupled with Bitcoin's performance, will propel the stock to new levels amidst ongoing discussions about market manipulation and dilution.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. (CRML) is garnering significant attention as discussions intensify around the U.S. administration's renewed interest in Greenland and its strategic rare earth deposits. The community is actively debating the potential for governmental partnerships and investment in CRML's Tanbreez project, viewing it as crucial for establishing Western supply chain independence for critical minerals.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is actively trending amid a surge in trading volume and technical breakouts, with the community highly focused on anticipated utility developments for 2026, including its Layer-2 mainnet, DePIN, and AI integrations. Supporters emphasize its Japanese regulatory compliance and perceived foundational strengths for secure data monetization, while skeptics point to historical volatility and question the immediate impact of its long-promised use cases.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

Ventyx Biosciences is trending strongly due to recent reports of advanced acquisition talks with Eli Lilly for over $1 billion, positioning its innovative oral inflammatory-disease pipeline at the center of a biopharma M&A surge. The community is actively discussing the substantial strategic value of Ventyx's NLRP3 inhibitors and their synergistic potential for cardiometabolic and neurodegenerative conditions. This has fueled speculation about a potential bidding war and intense short interest.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending due to a dramatic surge, fueled by speculation around accelerating AI infrastructure investments and perceived severe memory bottlenecks that are driving immense demand for storage. The community is sharply divided, with many celebrating its impressive, "unbelievable" run and anticipating further upside, while an equally vocal group warns of overvaluation and seeks shorting opportunities. This intense debate around its valuation reflects the broader sector's re-rating as memory and storage are increasingly seen as critical components in the new AI-driven economy.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending due to significant community debate and frustration over its stock's recent underperformance, contrasting sharply with a generally rising market. This divergence is largely driven by concerns about the company's perceived lag in the AI space and its leadership's strategic direction, exacerbated by a recent analyst downgrade. While many are critical of the current trajectory, some investors view the ongoing pullback as a potential buying opportunity ahead of anticipated product developments and upcoming earnings.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileye is trending following its acquisition of Mentee Robotics, signaling a strategic expansion into humanoid robots for factories and warehouses, alongside securing a significant ADAS deal with a major US automaker. This dual catalyst is generating considerable community discussion and driving positive analyst upgrades, highlighting Mobileye's integrated vision-and-radar approach as a strong competitor in the evolving autonomous driving and robotics landscape.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing significant volatility driven by recent analyst downgrades from major financial institutions, prompting widespread community discussion. Many perceive these downgrades as strategic market manipulation by competing banks, aiming to create cheaper entry points before upcoming strong earnings and potential S&P 500 inclusion. Despite the recent price action, a strong contingent of investors sees this as a prime 'buy the dip' opportunity, confident in SoFi's long-term growth as a leading fintech.

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Alumis is trending due to highly positive Phase 3 clinical trial results for its plaque psoriasis treatment, envudeucitinib, showcasing strong efficacy and a favorable safety profile. The community is buzzing with optimism, anticipating potential short squeezes and significant price target upgrades, positioning the drug as a "best-in-class" contender. While some discussion revolves around a proposed public offering, many are shrugging it off, focusing on the strong clinical data and market potential.

Aeva Technologies, Inc. develops sensing paradigm for autonomous vehicles and robotics. The firm offers drones, robotics, vehicle technology, and virtual and augmented reality products. The company was founded by Soroush Salehian Dardashti and Mina Rezk in 2017 and is headquartered in Mountain View, CA.

Aeva Technologies Inc

Aeva Technologies is trending following its pivotal partnership with NVIDIA to integrate its 4D LiDAR as a reference sensor for the DRIVE Hyperion autonomous vehicle platform, alongside an exclusive production contract with a major European OEM for Level 3 automated driving. The community views these developments as significant validation, propelling discussions about Aeva's potential as a Tier-1 LiDAR supplier for future autonomous systems and anticipating substantial long-term growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Piper Sandler downgraded ALEX stock to ‘Neutral’ from ‘Overweight’ and kept the price target unchanged at $21.</li><li>Alexander &amp; Baldwin announced on Monday that it would go private in a deal worth $2.3 billion.&nbsp;</li><li>The company will be acquired by a MW Group joint venture for $21.20 per share by the first quarter of 2026, the company said in a statement.&nbsp; &nbsp;</li></ul>Shares of Alexander &amp; Baldwin (ALEX) rallied over 38% on Tuesday morning after the announcement of the $2.3 billion take-private deal.The company’s outstanding shares will be acquired at $21.20 per share by a joint venture formed among MW Group, Blackstone Real Estate, and DivcoWest, expected to close by the first quarter of 2026. The all-cash deal represents a 40% premium to the company’s closing price as of Dec. 8, 2025.&nbsp;In addition, Alexander &amp; Baldwin announced a fourth-quarter (Q4) 2025 dividend of $0.35 per share, payable on January 8, 2026.&nbsp;<h2 class="st-heading-2">Street Action</h2>Meanwhile, Piper Sandler downgraded ALEX to ‘Neutral’ from ‘Overweight’ before, while keeping the price target intact at $21, as cited on TheFly. Piper said that it has revised its rating following the announcement and does not expect a competing bid to emerge.“Today, we are taking an important step toward our long-term vision for A&amp;B as stewards of Hawai'i's premier commercial real estate. As a private company supported by the deep real estate expertise and experience of our new ownership group, A&amp;B will have greater capacity to serve its tenants and communities,” President and CEO Lance Parker said.&nbsp;Alexander &amp; Baldwin is the only publicly traded real estate investment trust focused solely on Hawaiian commercial real estate. The company owns about four million square feet of commercial space in Hawai'i.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ALEX jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1276/154;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_09_at_8_30_30_PM_png_5f7959ea10.webp" alt="On Stocktwits, retail sentiment around ALEX jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels." width="1276" height="154"></figure>Shares of ALEX have climbed over 18% in the past year and returned almost 30% in the last five years.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com&nbsp;

Generic Image of Office Space (Photo by Fairfax Media via Getty Images via Getty Images)

Alexander & Baldwin Shares Shoot Through The Roof After $2.3B Take Private Deal – This Firm Has Downgraded The Stock

Shares of ALEX surged over 38% in pre-market trading while Piper Sandler downgraded the stock. 

Equity

Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries (TEVA), announced on Thursday that the U.S. Food and Drug Administration has approved a generic version of the Liraglutide injection known as Saxenda.Liraglutide Injection is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated to reduce excess body weight and maintain weight reduction long-term in adults as well as pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity. The drug is to be used in combination with a reduced-calorie diet and increased physical activity.“With this approval, and by launching a generic for Saxenda (liraglutide injection), we will provide patients in the U.S. the first ever generic GLP-1 product specifically indicated for weight loss,” <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.tevapharm.com/news-and-media/latest-news/teva-announces-fda-approval-and-launch-of-generic-saxenda-liraglutide-injection--first-generic-glp-1-/">said</a> Ernie Richardsen, Head of U.S. Commercial Generics at Teva. He added that it marks an important addition to the company’s generics portfolio.Saxenda, Novo Nordisk’s older obesity drug, had annual sales of $165 million as of June 2025, the company said. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TEVA">TEVA stock</a> trended within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_28_at_9_52_29_AM_png_ba7ec14e95.webp" alt="TEVA's Sentiment Meter and Message Volume as of 9:52 a.m. ET on Aug. 28, 2025 | Source: Stocktwits" width="625" height="64"><figcaption>TEVA's Sentiment Meter and Message Volume as of 9:52 a.m. ET on Aug. 28, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed surprise that the stock is not trading higher despite the approval.<stembedurl>https://stocktwits.com/RemitTekram/message/626845403</stembedurl>Another user sounded skeptical, saying that the stock would probably end the day in the red despite “explosive news.”<stembedurl>https://stocktwits.com/NoTradeAnymore/message/626842741</stembedurl>In the second quarter, Teva recorded revenue of $4.2 billion and adjusted and diluted earnings per share of $0.66. Generics product revenues in the U.S., however, fell 6% to $961 million, due to lower revenues from Lenalidomide capsules, the generic version of Revlimid, and Liraglutide injection 1.8mg, an authorized generic of Victoza, primarily driven by increased competition.TEVA stock is down 19% this year and approximately 3% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/lakeshore-biopharma-receives-revised-proposal-to-acquire-company/chs6JRRRdmm">LakeShore Biopharma Receives Revised Proposal To Acquire Company</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A very overweight woman with swollen feet stands on a scale that reads 145.1 kilograms. Overweight and obesity are increasing at a rapid pace worldwide. Photo: Pia Bayer/dpa (Photo by Pia Bayer/picture alliance via Getty Images)

This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More

The company’s U.S. affiliate announced that the U.S. Food and Drug Administration has approved a generic version of Liraglutide injection, known as Saxenda.

IYLD
iShares Morningstar Multi-Asset Income ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IYLD News

IYLDiShares Morningstar Multi-Asset Income ETF